MitraClip vs. TMVR: Understanding Mitral Valve Repair and Replacement

20 July 2026 | Dr. Bhavesh Roy

Introduction: Understanding Treatment for a Leaking Mitral Valve

The mitral valve is located between the left atrium and left ventricle, the two chambers on the left side of the heart. It opens to allow blood to move into the left ventricle and closes when the ventricle contracts, helping blood flow forward into the aorta.

Mitral regurgitation occurs when the valve does not close properly and some blood leaks backwards into the left atrium. Mild regurgitation may not cause symptoms, while more significant leakage can contribute to breathlessness, fatigue, changes in heart size and, in some patients, heart failure or abnormal heart rhythms.

Treatment depends on the severity and cause of the leakage, its effects on the heart, the patient’s symptoms, valve anatomy and overall health. Some people need regular monitoring and medication for associated conditions. Others may benefit from a valve procedure.

Surgical mitral valve repair is an important option for patients who can safely undergo surgery. For selected patients, catheter-based procedures may offer an alternative that avoids conventional open-heart surgery. Two terms patients may encounter are MitraClip and TMVR.

MitraClip is a device used during transcatheter edge-to-edge repair, or TEER. It helps the existing mitral valve close more effectively without replacing the entire valve. TMVR stands for transcatheter mitral valve replacement and refers to procedures that implant a replacement valve using a catheter-based approach.

Although both approaches can treat selected mitral valve conditions, they work differently and have distinct eligibility requirements and risks. This article explains their differences and the clinical factors that help a multidisciplinary heart team choose an appropriate treatment.

Table of Contents

• Recognising the Symptoms of Mitral Regurgitation
• What Is MitraClip?
• What Is Transcatheter Mitral Valve Replacement (TMVR)?
• Key Differences: Repair vs. Replacement
• The Recovery Process: What to Expect
• Which Procedure May Be Appropriate for You?
• Frequently Asked Questions
• Conclusion

Recognising the Symptoms of Mitral Regurgitation

Mitral regurgitation can develop gradually, and some people have no noticeable symptoms during the early stages. The importance of the condition depends on the amount of leakage, its cause, how the heart responds and whether other cardiac conditions are present.

As regurgitation becomes more significant, blood returning to the left atrium can increase pressure in the chambers and the blood vessels carrying blood from the lungs to the heart. In some cases, this contributes to fluid congestion and makes breathing more difficult.

Common symptoms

• Shortness of breath: Breathlessness during physical activity or when lying flat may occur when mitral regurgitation affects heart function or pressure in the lungs.
• Fatigue and reduced exercise tolerance: Some people find that routine activities become more tiring than before.
• Palpitations: A person may notice a fast, fluttering or irregular heartbeat. Atrial fibrillation can occur in association with mitral valve disease.
• Swelling of the legs or ankles: Fluid retention may develop in people with associated heart failure, although swelling has many possible causes.
• Lightheadedness: Some people report dizziness or lightheadedness, which requires assessment if persistent or recurrent.

These symptoms are not specific to mitral regurgitation. Breathlessness and tiredness can also occur with lung disease, anaemia, coronary artery disease and other conditions. An examination and appropriate investigations are needed to identify the cause.

How is mitral regurgitation diagnosed?

Echocardiography, an ultrasound examination of the heart, is a key test for assessing the mitral valve. It can help determine the severity of the leakage, examine the valve leaflets and supporting structures, and evaluate heart chamber size and pumping function.

Additional testing may be needed when the initial findings do not fully explain the symptoms or when a valve procedure is being considered. Transoesophageal echocardiography uses an ultrasound probe in the oesophagus to provide more detailed views of the valve. Cardiac CT can help assess anatomical features and procedural feasibility, particularly when replacement is being considered.

Not every person with mitral regurgitation needs an intervention. Some people require periodic echocardiograms and monitoring, while others may need medicines to manage associated heart failure, fluid retention or rhythm problems. The decision to repair or replace a valve depends on the complete clinical assessment.

Severe or sudden breathlessness, chest pain, fainting or rapidly worsening symptoms require urgent medical assessment. Do not assume that these symptoms are caused by a valve condition without appropriate evaluation.

What Is MitraClip?

MitraClip is a catheter-delivered device used for transcatheter edge-to-edge repair, commonly abbreviated as TEER. This procedure aims to reduce mitral regurgitation by bringing selected portions of the valve leaflets together so that the valve closes more effectively.

TEER is different from replacing the valve. The patient’s native mitral valve remains in place, and the clip modifies how the leaflets meet during each heartbeat. The amount of regurgitation may decrease, although the degree of improvement varies according to the patient’s anatomy, valve disease and procedural result.

How is the procedure performed?

The procedure is generally performed through a vein in the groin. A catheter is guided into the right side of the heart and across the dividing wall between the upper chambers to reach the left atrium. This route is called the transseptal approach.

Using echocardiographic guidance, often including transoesophageal echocardiography, and X-ray imaging, the team positions the device across the mitral valve. The clip is attached to selected portions of the valve leaflets, allowing them to come together more closely. The team assesses the residual leakage and the valve’s function before completing the procedure.

The exact procedural steps, imaging approach and anaesthesia plan depend on the patient’s circumstances and the centre’s practice. General anaesthesia is commonly used, but selected procedures may be performed with a different sedation strategy.

Who may be considered for MitraClip or TEER?

TEER may be appropriate for carefully selected patients with significant symptomatic mitral regurgitation whose valve anatomy is suitable and for whom open surgery is considered high risk or unsuitable. It is also an option for certain patients with secondary, or functional, mitral regurgitation whose symptoms and leakage persist despite appropriate guideline-directed medical treatment.

Primary mitral regurgitation occurs when the valve itself has a structural problem, such as prolapse, a flail leaflet or another abnormality of the valve apparatus. Secondary mitral regurgitation occurs when changes in the heart’s size or function prevent the valve from closing properly, even though the leaflets may not be the primary problem.

These forms of regurgitation are evaluated differently. For patients with primary mitral regurgitation who are suitable surgical candidates, surgical repair may remain the preferred option because it can provide a durable correction. TEER can be considered when the clinical benefits of surgery are outweighed by its risks or when other specific selection criteria are met.

For selected patients with secondary mitral regurgitation, the heart team first assesses whether heart failure treatment and other indicated therapies have been optimised. TEER may be considered when significant symptoms and leakage remain and the patient meets appropriate anatomical and clinical criteria.

What are the potential benefits and limitations?

For an appropriate candidate, TEER can reduce mitral regurgitation and may improve symptoms, functional capacity and quality of life. In selected patient groups, clinical evidence has also demonstrated benefits in heart failure-related outcomes.

However, TEER does not completely eliminate leakage in every case, and some patients may have residual regurgitation or develop other valve-related issues. Potential complications include bleeding or vascular injury, stroke, problems involving the heart or valve, infection and other risks associated with catheter-based cardiac procedures.

The procedure may also be unsuitable when the valve leaflets are too short, heavily damaged, excessively calcified in the relevant area, or when the valve anatomy creates an unacceptable risk of narrowing after clipping. A reduced mitral valve opening can impair blood flow, so the team must assess both the expected reduction in leakage and the remaining valve area.

The clip is not a universal solution for every leaking mitral valve. Appropriate patient selection and detailed imaging are essential to determine whether the expected benefit justifies the risks.

What Is Transcatheter Mitral Valve Replacement (TMVR)?

TMVR stands for transcatheter mitral valve replacement. Instead of bringing portions of the existing valve leaflets together, the procedure implants a replacement valve using a catheter-based approach. The new valve is intended to take over the function of controlling blood flow through the mitral valve.

TMVR is a broad category rather than a single procedure or device. Different approaches are used for different types of mitral valve disease, and device availability, approval and clinical experience vary by country and treatment centre.

How does TMVR work?

Before TMVR, clinicians assess the valve anatomy and surrounding heart structures carefully. Echocardiography and cardiac CT may be used to understand the shape and dimensions of the valve opening, the relationship between the valve and nearby structures, and whether the replacement device can be positioned safely.

During the procedure, a replacement valve is delivered through a catheter or, for some approaches, through a surgical or hybrid access route. Depending on the type of TMVR, access may be transseptal through a vein, transapical through the heart’s apex, or another specialised route.

The replacement valve must be securely positioned and function correctly. Its design and anchoring mechanism depend on the specific device and the anatomy being treated. Not every TMVR procedure involves the same delivery system, access route or procedural steps.

Different forms of TMVR

TMVR procedures can be broadly grouped according to the valve being treated:

• Valve-in-valve: A transcatheter replacement valve is placed inside a previously implanted surgical biological mitral valve that has deteriorated or stopped functioning adequately. This can be an option for selected patients, particularly when repeat surgery carries substantial risk.
• Valve-in-ring: A replacement valve is placed within a ring implanted during an earlier surgical mitral valve repair. The ring’s shape and dimensions must be suitable, and procedural planning is important.
• Valve-in-mitral-annular-calcification (valve-in-MAC): A transcatheter valve may be implanted in selected patients with severe mitral annular calcification. These procedures can be technically challenging because calcium distribution, anchoring and nearby heart structures create specific risks.
• Dedicated TMVR for native valve disease: Specialised replacement systems have been developed for diseased native mitral valves. Availability, regulatory status and suitability depend on the specific device and jurisdiction; some approaches remain limited to selected centres or clinical studies.

These categories should not be treated as identical. A replacement procedure inside a failed surgical biological valve may involve a different level of predictability and different anatomical challenges from replacing a native valve affected by severe calcification.

When might TMVR be considered?

TMVR may be discussed when a diseased mitral valve needs replacement and a transcatheter approach is considered suitable. It can be particularly relevant for selected patients with a failing surgical biological valve or prior repair ring who have substantial risk from repeat open surgery.

Some patients with native valve disease and extensive mitral annular calcification may also be considered, but these procedures require careful assessment because the risks can be significant. A dedicated TMVR device may be suitable for certain native valve conditions where such technology is available, but the evidence and eligibility requirements vary by device and indication.

It is not accurate to assume that TMVR is required whenever a valve is calcified or that a clip cannot work in every calcified valve. Some patients with calcification may still be candidates for TEER, while other anatomical features can make either approach unsuitable. A specialist heart team must evaluate the individual valve.

What are the potential risks and limitations?

TMVR requires detailed planning because the mitral valve is located close to other important structures. Potential complications can include bleeding, stroke, valve displacement or leakage around the replacement valve, obstruction of the left ventricular outflow tract, damage to nearby structures and other risks related to the procedure or implanted device.

Some forms of TMVR can cause narrowing of the route through which blood leaves the left ventricle. This risk is particularly important when planning replacement in certain native-valve or heavily calcified anatomies. Imaging and procedural planning are used to assess whether a replacement is feasible and to help reduce avoidable risks.

TMVR does not guarantee complete symptom relief or freedom from later valve problems. Patients require follow-up to assess valve function, heart function and any complications. Medication after the procedure is individualised according to the valve, the patient’s rhythm, other medical conditions and the treating team’s instructions.

Key Differences: Repair vs. Replacement

MitraClip-based TEER and TMVR can both be delivered using catheter-based techniques, but they address mitral valve disease in different ways. The best choice depends on more than whether a valve leaks or contains calcium.

Neither approach is automatically superior. TEER may be attractive when the anatomy permits a meaningful reduction in regurgitation without creating excessive narrowing. Replacement may be relevant when repair is unsuitable or when an existing biological valve has failed and a valve-in-valve approach is feasible.

For patients who can safely undergo conventional surgery, surgical mitral valve repair or replacement may remain the preferred option depending on the disease. Catheter-based treatment is selected after considering expected benefit, durability, procedural risk and the patient’s preferences.

The Recovery Process: What to Expect

Recovery after a catheter-based mitral procedure may be less burdensome than recovery after open-heart surgery for some patients. However, it is not possible to promise that every patient will leave hospital after one or two nights or return to normal activity within a week.

During the hospital stay

After TEER or TMVR, the medical team monitors heart rhythm, blood pressure, breathing, the access site and overall clinical stability. Echocardiography or other investigations may be performed to evaluate the valve result and heart function.

Some patients recover without major complications and can leave hospital after a relatively short stay. Others need longer monitoring because of pre-existing heart failure, kidney disease, rhythm problems, access-site complications or issues identified during the procedure.

Returning to everyday activities

Activity is increased according to the procedure and the patient’s condition. Instructions may cover walking, lifting, bathing, driving, returning to work and caring for the catheter access site. Patients who have a more complex procedure or a different access route may have different restrictions.

Follow the discharge instructions and contact the treating team if symptoms worsen or recovery is not progressing as expected. Do not use another person’s recovery timeline as a substitute for individual advice.

Medication and follow-up

Medication plans after mitral intervention vary. Patients may need treatment for heart failure, blood pressure, cholesterol or abnormal heart rhythms. Antithrombotic treatment depends on the procedure, implanted device, history of atrial fibrillation or other conditions, and the treating team’s plan.

Do not start, stop or change blood thinners or other prescribed medicines without medical advice. Attend follow-up appointments so the team can assess symptoms, review echocardiography findings when indicated and monitor the performance of the repaired or replacement valve.

Even if breathlessness or fatigue improves, regular follow-up remains important. A procedure treats a specific valve problem but does not necessarily remove every underlying heart condition or cardiovascular risk.

Which Procedure May Be Appropriate for You?

There is no single procedure that is right for every patient with mitral valve disease. The decision between TEER, TMVR, conventional surgery or medical management requires a detailed assessment by a multidisciplinary heart team. The team may include a cardiologist with expertise in valve disease, an interventional cardiologist, a cardiac surgeon, cardiac imaging specialists and other professionals as needed.

1. Identify the cause and severity of the valve problem

The first step is to establish whether mitral regurgitation is primary or secondary, how severe it is and whether it explains the patient’s symptoms. Echocardiography helps assess the valve and heart, while other investigations may be needed to evaluate coronary disease, heart failure or additional conditions.

2. Assess whether the anatomy is suitable for repair

For TEER, the team assesses whether the valve leaflets can be safely and effectively brought together, whether enough valve opening will remain after clipping and whether the expected reduction in regurgitation is clinically meaningful.

For replacement, clinicians consider the dimensions of the annulus, the potential to anchor the device, the relationship to nearby structures and the risk of obstructing blood flow out of the left ventricle. CT and detailed echocardiography may be important components of this assessment.

3. Consider surgery, medical treatment and other options

If surgery is a reasonable option, surgical repair may be preferred for certain forms of primary mitral regurgitation. For secondary regurgitation, treatment of heart failure and other underlying conditions is important, and TEER may be appropriate for selected patients who remain symptomatic despite optimal medical treatment.

TMVR may be an option for specific valve anatomies or a failed surgical biological valve, depending on the device and local availability. In some cases, neither TEER nor TMVR is suitable, and the heart team may recommend surgery, other management options or continued monitoring.

4. Weigh potential benefits against risks

The heart team considers likely symptom improvement, expected effect on heart function, procedural risks, other medical conditions, recovery needs and longer-term follow-up. Patients should also have the opportunity to ask about uncertainty, alternative treatments and what may happen if an intervention is deferred.

When comparing options, the goal is not simply to choose the procedure that sounds least invasive. The aim is to find a clinically appropriate treatment that offers a meaningful expected benefit for the individual patient.

Frequently Asked Questions

1. Are MitraClip and TMVR the same procedure?

No. MitraClip is a device used for transcatheter edge-to-edge repair, which brings selected mitral valve leaflets together to reduce leakage. TMVR replaces the valve using a transcatheter approach. They have different procedural steps, anatomical requirements and potential risks.

2. Is MitraClip suitable for every patient with mitral regurgitation?

No. TEER is considered for selected patients with significant symptomatic mitral regurgitation whose valve anatomy and clinical condition are appropriate. Some patients are better served by surgical repair or replacement, while others may need medical management and monitoring.

3. Is TMVR only used when the mitral valve is heavily calcified?

No. TMVR includes several types of replacement procedures, including valve-in-valve for a failed surgical biological valve and valve-in-ring for selected patients with a previous repair ring. Some approaches address native mitral valve disease. The suitable option depends on the anatomy, clinical indication and device availability.

4. Does TMVR completely cure mitral regurgitation?

TMVR is intended to replace the valve and treat the relevant valve dysfunction, but it cannot guarantee complete symptom relief or freedom from complications. The result depends on anatomy, device position, heart function and the patient’s overall clinical condition. Continued follow-up is important.

5. Are patients awake during MitraClip or TMVR?

The anaesthesia plan varies with the procedure, access route, patient factors and centre practice. General anaesthesia is commonly used for many TEER procedures, while some centres may use a sedation-based approach in selected patients. TMVR anaesthesia requirements also vary. The treating team can explain the planned approach.

6. How long does recovery take?

There is no fixed recovery timeline for everyone. Recovery depends on the procedure, access route, other medical conditions, hospital course and whether complications occur. Your team will advise when to resume activity, drive, work and exercise.

7. Does TMVR last as long as surgical valve replacement?

Durability depends on the type of device, indication, implantation technique and length of follow-up available. The evidence differs between valve-in-valve procedures, valve-in-ring procedures, valve-in-MAC procedures and dedicated native-valve TMVR systems. Ask the treating team about the evidence relevant to the specific device and procedure being considered.

8. Can medication alone treat mitral regurgitation?

Medication may help control symptoms or related conditions such as heart failure and abnormal heart rhythms, but it does not physically repair a valve that is structurally damaged. Depending on severity and clinical circumstances, a person may need monitoring, a valve intervention or surgery. Treatment should be individualised.

Conclusion

MitraClip-based TEER and TMVR are different approaches to treating selected mitral valve conditions. TEER helps the existing valve close more effectively by bringing portions of the leaflets together. TMVR implants a replacement valve through a catheter-based or specialised access approach.

TEER can be appropriate for selected patients with significant symptomatic mitral regurgitation when the valve anatomy is suitable and clinical criteria are met. TMVR may be considered for particular situations, including a failed surgical biological valve, a previous repair ring or selected forms of native mitral valve disease. Its suitability and availability vary by device and indication.

Neither approach is automatically better, and heavily calcified anatomy alone does not determine the correct choice. Echocardiography, sometimes supplemented by CT and other investigations, helps the heart team evaluate the valve, procedural feasibility, possible risks and likely benefits.

Patients can discuss the available options with their cardiology team, including the role of surgery, medical treatment, catheter-based repair or replacement, expected recovery and long-term monitoring. A treatment decision should be based on individual clinical findings rather than a general comparison alone.